Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI

NCT05758896 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

280

Enrollment

INDIV

Sponsor class

Conditions

Contrast Induced Acute Kidney Injury

Interventions

DRUG: Isuzinaxib (APX-115)
DRUG: Placebo

Sponsor

Aptabio Therapeutics, Inc.